Browse drugs

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…systemic palliative chemotherapy with NALIRIFOX, mFOLFIRINOX or Gem/NabP between January 2021 and July 2024. Key eligibility criteria re…

…mens alone (PF vs GP) and (I–L) depict the oral regimens alone (capecitabine vs S-1); within each panel set the endpoints are, respectively,…

… consistent with the known toxicity profiles of carboplatin and gemcitabine. Notably, grade ≥3 AEs were predominantly hematological, with m…

…l pharmacy production workflows.Results Approximately 2,000 RTU gemcitabine bags were used, accounting for 82% of total production. Each RT…

…t otherwise specified (PTCL-NOS). The disease was refractory to brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone, SMILE and pr…

…BTC were enrolled from five centers in China. Patients received pembrolizumab (200 mg, every 3 weeks), lenvatinib (8 or 12 mg daily), and mod…

…going trials using a novel intravesical drug delivery system of gemcitabine, gene therapy-based biological response modifiers with or witho…

…ounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubic…

…on, and enhanced homing to solid tumors. Preparative regimen of Gemcitabine/Docetaxel has known activity across relapsed pediatric sarcomas…

…ansen JS, Larsen FO, Theile S, Hasselby JP, Willemoe GL, et al. Nivolumab with or without ipilimumab combined with stereotactic body radi…

… for Gem/NabP. Recorded grade ≥3 toxicities appeared lower with NALIRIFOX, although cross-regimen safety comparisons were limited by retr…